Season One of Surfing The NASH Tsunami
Vlad Ratziu and Joern Schattenberg join the Surfers to wrap up our conversation about this year’s AASLD meeting
Mary Rinella joins the Surfers for a final day of AASLD 2020 reviewing focusing equally on lessons in drug development and the crying need for social and dietary education, particularly for parents and children.
Reviews of Phase 2 drug trials and diagnostic strategies reveal that NASH is close to multiple breakthroughs
Ep 35 – Saturday at TLMdX 2020 from AASLD: Lean NASH, exciting Diagnostics and Patient-Reported Outcomes as an Endpoint
Manal Abdelmalek joins the Surfers to review some of Saturday’s most exciting presentations and posters from AASLD 2020, followed by a discussion of an exciting new hand-held diagnostic
Prof. Dr. Jörn M. Schattenberg joins the Surfers to discuss his recent article in Expert Opinion on Investigational Drugs dissecting recent drug trial failures.
Stephen Harrison, Roger Green and our guest Surfer, Dr. Manal Abdelmalek, identify pivotally important presentations and posters from The Digital Liver Meeting 2020
Louise Campbell, Donna Cryer and Naim Alkhouri identify pivotally important presentations and posters from The Digital Liver Meeting 2020
Guest Surfer and regular listener Dr. Ian Rowe joins the Surfers to discuss how everyday patient treatment in the clinic once was and how COVID-19 and the news we discuss weekly on SurfingNASH have changed practice.
On the six-month anniversary of SurfingNASH’s first episode, the Surfers stop to consider how much has changed for NASH stakeholders since April
Matt Kelly, Chief Innovation Officer at Perspectum, Ltd., joins the Surfers to the discuss early findings from the COVERSCAN study which looks at the relationship between COVID-19 infection and major end organ systems.
Stephen Harrison leads the Surfers through a review of FGF-21s and other exciting drug development news
The Surfers discuss four issues that are likely to affect how our thinking about NASH diagnosis, education, and treatment might evolve over the next three months.
“Beyond the Biopsy”— How NASH Therapy Will Improve When Non-Invasive Tests Become The Standard – Ep 26
The Surfers discuss the Global Liver Institute’s campaign to educate and motivate key stakeholder groups on the value of non-invasive liver testing.
The Surfers and guest Joern Schattenberg consider the implications of a Digital ILC presentation stating that the liver, not cardiovascular disease, is the leading cause of death for NAFLD patients.
Professors Joern Shcattenberg and Vlad Ratziu join the Surfers to discuss the lessons and findings we can take away from Digital ILC 2020
Day Three into EASL Digital ILC 2020
Day Two into EASL Digital ILC 2020
Day One into EASL Digital ILC 2020
The group discusses the plusses and minuses of digital conferences compared to traditional in-person events.
Patient advocates envision future digital technologies that can provide tremendous benefit to them and how government agencies provide support for better disease knowledge and care
Patient advocates discuss how doctors and other providers can serve patient needs better
FOCUS: More of the presentations that will make NASH/NAFLD news at the Digital International Liver Congress later this month
How passionate providers (nurses, dieticians, and physicians) can motivate patient lifestyle changes.
FOCUS: Some of the presentations that will make NASH/NAFLD news next month
NASH is not merely a byproduct of obesity.
FOCUS: Three sets of tools that will improve NASH disease understanding
Decoding the message of Intercept’s Complete Response Letter
CONSENSUS: the big story will be the regrowth of COVID-19 in the US and its implications
What would create greater value for patients and providers?
SurfingNASH celebrates a growing and increasingly important global event for the Fatty Liver community.
Room for improvement
Reviewing press releases reporting preliminary findings from six recently announced Phase 2 trials
Exploring the controversy over the name(s) to use when describing Fatty Liver disease(s)
Clinical trial results that are changing how we look at NASH
Three possible scenarios for development of the NASH market.
Critical considerations for companies developing NASH drugs
What investors want to know about NASH development during the pandemic.
Navigating NAFLD/NASH clinical trials through the pandemic
Hep Dynamics LLC announces the launch of a new podcast series. “Surfing the NASH Tsunami”, focused on challenges, solutions and news in NASH drug development.